colorectal cancer therapeutics in major developed markets ... · colorectal cancer therapeutics in...
TRANSCRIPT
THERAPY ANALYSIS
Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased
Uptake of High Priced Drugs to Offset the Impact of Generics
Report Code: GBIHC352MR Published: January 2015
www.gbiresearch.com
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 2
GBI Research Report Guidance
The report begins with an executive summary detailing the key points driving the CRC market in eight major markets: the US, the UK, France, Germany, Spain, Italy, Japan and Canada.
Chapter two provides an introduction to CRC, detailing etiology, epidemiology, diagnostic techniques, disease staging and typical prognoses for patients. An analysis of current treatment algorithms and options is also included.
Chapter three offers detailed analysis of the drugs currently marketed for this indication: 5-FU, Xeloda, Camptosar, Eloxatin, Avastin, Zaltrap, Vectibix, Stivarga and Erbitux. This includes key characteristics, covering safety and efficacy, clinical trial outcomes, tolerability, dosing, administration, historical sales, prices and overall competitive strength. These products are also compared in a comprehensive heat map.
Chapter four provides detailed analysis of the pipeline for CRC according to stage of development, molecule type, program type, mechanism of action and molecular target. It also analyses recent clinical trials in this indication by enrollment, duration and failure rate. Finally, promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
Chapter five supplies market forecasts for the CRC market, including epidemiology, treatment use patterns, pricing, and market size, for the forecast period from 2013 to 2020. The eight major markets are covered and data are presented at a country level with further analysis of key market drivers and barriers.
Chapter six describes the major deals that have taken place in the global CRC market in recent years. This coverage analyzes licensing and co-development agreements, segmented by stage of development, year, molecule type, mechanism of action and value. Network graphs for these deals by location of company headquarters are also included.
An appendix is included in chapter seven. This lists key definitions, explanations of abbreviations, details of the methodology and sources used.
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 3
Executive Summary
Moderate growth expected for the Colorectal Cancer (CRC) market
The value of the Colorectal Cancer (CRC) therapeutics market across eight major countries – the US, the UK, France, Germany, Spain, Italy, Japan and Canada – amounted to $XX billion in 2013, and is expected to increase moderately at a Compound Annual Growth Rate (CAGR) of XX% to $XX billion in 2020. The US had the largest market value in 2013, with $XX billion, equivalent to a global share of XX%, followed by Japan with $XX billion or XX% and Germany with $XXm or XX%. Spain had the lowest market share and value of the leading eight with $XXm or XX%.
Of the markets covered in the report, Japan is expected to register growth at the fastest pace, with a CAGR of XX%. However, this moderate growth will be stymied by the expected uptake of low-cost biosimilar versions of bevacizumab and cetuximab, due to the expected patent expiration of Avastin and Erbitux in the latter half of the forecast period. A number of generic versions of capecitabine are also expected to be launched, which will be affecting the market. However, the impact of patent expirations will be offset by the launch of premium priced emerging therapies.
Stivarga (regorafenib) is expected to be one of the biggest drivers of growth in the CRC market, due primarily to its expected line extension as a maintenance treatment in the first-line metastatic setting as a maintenance treatment for patients with resected liver metastases. The launch of Lonsurf (TAS-102), which was approved in Japan in 2014, in the third- and fourth-line settings will further increase the pharmacological treatment rates in these lines, which would give patients a more tolerable alternative to Stivarga. The efficacy shown by TAS-102 is similar to that of regorafenib, but prescribers view it as having a more tolerable safety profile.
The launch of Zaltrap (ziv-aflibercept) by Sanofi/Regeneron has given patients an alternative angiogenesis inhibitor in the second-line setting, which will be prescribed primarily to patients who have progressed quickly on bevacizumab in the first-line setting. Eli Lilly’s Cyramza (ramucirumab), which will target patients in a similar setting as Zaltrap, is also expected to be launched in 2015. The uptake of Cyramza in this setting will be limited, predominantly because of its premium pricing over Zaltrap.
Colorectal Cancer Therapeutics, Global, Market Size ($bn), 2013–2020
2013 2014 2015 2016 2017 2018 2019 2020
Mar
ket s
ize
($bn
)
Low variance Medium variance High variance Projected
Source: GBI Research, Proprietary Pipeline Products Database; GBI Research, Proprietary Marketed Products Database
Stivarga is expected to be one of the biggest drivers of growth in the CRC market.
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 5
1 Table of Contents
1 Table of Contents .............................................................................................................................................5 1.1 List of Tables ......................................................................................................................................... 7 1.2 List of Figures ........................................................................................................................................ 7
2 Introduction ........................................................................................................................................................9 2.1 Colorectal Cancer ................................................................................................................................9 2.2 Symptoms ..............................................................................................................................................9 2.3 Epidemiology ........................................................................................................................................9 2.4 Pathophysiology ................................................................................................................................. 10
2.4.1 Histology ..................................................................................................................................... 10 2.4.2 Genetic Basis .............................................................................................................................. 10 2.4.3 Etiology of Colorectal Cancer .................................................................................................. 11
2.5 Diagnosis ............................................................................................................................................. 12 2.5.1 Digital Rectal Examination ....................................................................................................... 12 2.5.2 Fecal Occult Blood Test ........................................................................................................... 12 2.5.3 Flexible Sigmoidoscopy ........................................................................................................... 12 2.5.4 Colonoscopy............................................................................................................................... 13 2.5.5 Virtual Colonoscopy .................................................................................................................. 13 2.5.6 Double Contrast Barium Enema ............................................................................................. 14
2.6 Prognosis and Disease Staging....................................................................................................... 14 2.7 Treatment Options ............................................................................................................................. 16
2.7.1 Surgery and Radiation Therapy .............................................................................................. 16 2.7.2 Chemotherapy ........................................................................................................................... 16 2.7.3 Targeted Therapies ................................................................................................................... 17 2.7.4 Resistance to Pharmacological Therapies............................................................................ 17 2.7.5 Treatment Guidelines ............................................................................................................... 18
3 Marketed Products ........................................................................................................................................ 22 3.1 Key Marketed Products .................................................................................................................... 22
3.1.1 Immunotherapies ...................................................................................................................... 22 3.1.2 Targeted Therapies .................................................................................................................. 26 3.1.3 Hyperthermic Intraperitoneal Chemotherapy ...................................................................... 31
3.2 Heat Map for Marketed Products .................................................................................................... 31 4 Pipeline Analysis ............................................................................................................................................ 34
4.1 Overall Pipeline.................................................................................................................................. 34 4.2 Pipeline Analysis by Molecule Type .............................................................................................. 35 4.3 Pipeline Analysis by Mechanism of Action ................................................................................... 36 4.4 Clinical Trials ...................................................................................................................................... 38 4.5 Failure Rate ........................................................................................................................................ 38 4.6 Clinical Trial Size ............................................................................................................................... 40 4.7 Duration............................................................................................................................................... 42 4.8 Promising Drug Candidates in Pipeline ........................................................................................ 44
4.8.1 Lonsurf (TAS-102 (tipiracil + trifluridine)) – Taiho Pharmaceutical ................................... 44 4.8.2 Cyramza – ramucirumab – Eli Lilly and Company .............................................................. 44 4.8.3 TS-1/Teysuno (tegafur + gimeracil + oteracil) – Taiho Pharmaceutical ........................... 45 4.8.4 CPP-1X (eflornithine hydrochloride) + sulindac – Cancer Prevention Pharmaceuticals
...................................................................................................................................................... 46 4.8.5 MelCancerVac – DanDrit Biotech ..........................................................................................47 4.8.6 Xilonix – XBiotech .................................................................................................................... 48 4.8.7 Nintedanib – Boehringer Ingelheim...................................................................................... 49
5 Market Forecast to 2020 ............................................................................................................................. 50 5.1 Global Market ..................................................................................................................................... 50
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 6
5.1.1 Treatment Use Patterns .......................................................................................................... 50 5.1.2 Market Size ................................................................................................................................ 50
5.2 North America .................................................................................................................................... 52 5.2.1 Treatment Use Patterns .......................................................................................................... 52 5.2.2 Annual Cost of Therapy ........................................................................................................... 52 5.2.3 Market Size ................................................................................................................................ 53
5.3 Top Five European Markets ............................................................................................................ 54 5.3.1 Treatment Use Patterns .......................................................................................................... 54 5.3.2 Annual Cost of Therapy ........................................................................................................... 56 5.3.3 Market Size ................................................................................................................................ 57
5.4 Japan ................................................................................................................................................... 58 5.4.1 Treatment Use Patterns .......................................................................................................... 58 5.4.2 Annual Cost of Therapy ........................................................................................................... 59 5.4.3 Market Size ................................................................................................................................ 60
5.5 Drivers and Barriers for the Colorectal Cancer Therapeutics in Major Developed Markets to 2020................................................................................................................................................. 61
5.5.1 Drivers .......................................................................................................................................... 61 5.5.2 Barriers ....................................................................................................................................... 62
6 Deals and Strategic Consolidations ........................................................................................................... 64 6.1 Licensing Agreements ..................................................................................................................... 64
6.1.1 Major Licensing Deals ............................................................................................................. 67 6.2 Co-development Agreements ........................................................................................................ 68
6.2.1 Major Co-development Agreements .................................................................................... 70 7 Appendix .......................................................................................................................................................... 71
7.1 All Pipeline Drugs by Phase ............................................................................................................. 71 7.1.1 Discovery..................................................................................................................................... 71 7.1.2 Preclinical ................................................................................................................................... 72 7.1.3 IND/CTA-Filed ............................................................................................................................73 7.1.4 Phase I .........................................................................................................................................73 7.1.5 Phase II ........................................................................................................................................74 7.1.6 Phase III ...................................................................................................................................... 75
7.2 Market Forecasts to 2020 ............................................................................................................... 75 7.2.1 Global .......................................................................................................................................... 75 7.2.2 US ................................................................................................................................................ 75 7.2.3 Canada ....................................................................................................................................... 76 7.2.4 UK ................................................................................................................................................ 76 7.2.5 France ......................................................................................................................................... 76 7.2.6 Germany ...................................................................................................................................... 77 7.2.7 Italy ............................................................................................................................................... 77 7.2.8 Spain ............................................................................................................................................ 77 7.2.9 Japan............................................................................................................................................ 77
7.3 Market Definitions ............................................................................................................................. 78 7.4 Abbreviations ..................................................................................................................................... 78 7.5 References .......................................................................................................................................... 81 7.6 References for Heat Map ................................................................................................................. 86 7.7 Research Methodology .................................................................................................................... 87
7.7.1 Coverage .................................................................................................................................... 87 7.7.2 Secondary Research ................................................................................................................ 87 7.7.3 Primary Research ...................................................................................................................... 88 7.7.4 Therapeutic Landscape ........................................................................................................... 88 7.7.5 Geographical Landscape ......................................................................................................... 91 7.7.6 Pipeline Analysis ........................................................................................................................ 91
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 7
7.8 Expert Panel Validation ..................................................................................................................... 91 7.9 Contact Us ........................................................................................................................................... 91 7.10 Disclaimer ............................................................................................................................................ 91
1.1 List of Tables
Table 1 Colorectal Cancer Therapeutics, Global, TNM Staging, 2013 .............................................15 Table 2 Surgical Options for Colorectal Cancer................................................................................16 Table 3 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2014 ..............71 Table 4 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2014 .............72 Table 5 Colorectal Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed), 2014 ......73 Table 6 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2014 ..................73 Table 7 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2014 .................74 Table 8 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2014 ................75 Table 9: Colorectal Cancer Therapeutics, Global, Forecast Data, 2013–2020.................................75 Table 10: Colorectal Cancer Therapeutics, US, Forecast Data, 2013–2020 ......................................75 Table 11: Colorectal Cancer Therapeutics, Canada, Forecast Data, 2013–2020...............................76 Table 12: Colorectal Cancer Therapeutics, UK, Forecast Data, 2013–2020 ......................................76 Table 13: Colorectal Cancer Therapeutics, France, Forecast Data, 2013–2020 ................................76 Table 14: Colorectal Cancer Therapeutics, Germany, Forecast Data, 2013–2020 ............................77 Table 15: Colorectal Cancer Therapeutics, Italy, Forecast Data, 2013–2020.....................................77 Table 16: Colorectal Cancer Therapeutics, Spain, Forecast Data, 2013–2020 ..................................77 Table 17: Colorectal Cancer Therapeutics, Japan, Forecast Data, 2013–2020 .................................77 Table 18: Colorectal Cancer Market, References for Heat Map ..........................................................86
1.2 List of Figures
Figure 1: Colorectal Cancer Therapeutics, Global, European Society for Medical Oncology Treatment Guidelines (Colorectal Cancer at Stage I to III) ...................................................19
Figure 2: Colorectal Cancer Therapeutics, Global, European Society for Medical Oncology Treatment Guidelines (Colorectal Cancer at Stage IV) ........................................................20
Figure 3: Colorectal Cancer Therapeutics, Global, Heat Map (Marketed Products) ..........................33 Figure 4: Colorectal Cancer Therapeutics, Global, Pipeline by Stage of Development and Program
Type, 2014 .............................................................................................................................34 Figure 5: Colorectal Cancer Therapeutics, Global, Pipeline by Molecule Type and Stage of
Development, 2014 ...............................................................................................................35 Figure 6: Colorectal Cancer Therapeutics, Global, Pipeline by Mechanism of Action and Stage of
Development, 2014 ...............................................................................................................37 Figure 7: Colorectal Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2014 .....................39 Figure 8: Colorectal Cancer Therapeutics, Global, Clinical Trial Size, 2014 .......................................41 Figure 9: Colorectal Cancer Therapeutics, Global, Clinical Trial Duration (months), 2014 .................43 Figure 10: Colorectal Cancer Therapeutics, Global, Treatment Use Patterns (‘000) and Market Size
($bn), 2013–2020 .................................................................................................................51 Figure 11: Colorectal Cancer Therapeutics, US and Canada, Treatment Use Patterns (‘000), 2013–
2020......................................................................................................................................52 Figure 12: Colorectal Cancer Therapeutics, US and Canada, Annual Cost of Therapy ($), 2013–2020
...............................................................................................................................................53 Figure 13: Colorectal Cancer Therapeutics, US and Canada, Market Size ($m), 2013–2020 .............54 Figure 14: Colorectal Cancer Therapeutics, Top Five European Markets, Treatment Use Patterns
(‘000), 2013–2020 ................................................................................................................55 Figure 15: Colorectal Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($),
2013–2020 ...........................................................................................................................56 Figure 16: Colorectal Cancer Therapeutics, Top Five European Markets, Market Size ($m), 2013–
2020......................................................................................................................................58 Figure 17: Colorectal Cancer Therapeutics, Japan, Treatment Use Pattern, 2013–2020 ...................59 Figure 18: Colorectal Cancer Therapeutics, Japan, Annual Cost of Therapy, 2013–2020..................60
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 8
Figure 19: Colorectal Cancer Therapeutics, Japan, Market Size ($m), 2013–2020 .............................61 Figure 20: Colorectal Cancer Therapeutics, Global, Licensing Deals by Geography, 2006–2014 .....65 Figure 21: Colorectal Cancer Therapeutics, Global, Licensing Deals by Phase, Value, Mechanism of
Action, 2006–2014 ...............................................................................................................66 Figure 22: Colorectal Cancer Market, Global, Co-development Deals by Geography and by Value,
2006–2014 ...........................................................................................................................69 Figure 23: GBI Research Market Forecasting Model ............................................................................90
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 9
2 Introduction
This report contains estimations for 2013 and forecasts until 2020 for Colorectal Cancer (CRC) therapeutics in eight major markets: the US, the UK, France, Germany, Spain, Italy, Japan and Canada. The five-year prevalence is based on annual incidence over five years and takes into account the five-year survival rate. This produces a figure that reflects the number of surviving patients who were diagnosed with CRC in the previous five years and are therefore more likely to undergo pharmacological treatment for the disease than those diagnosed XX or more years earlier. The five-year prevalence population of CRC in these markets was estimated at XX in 2013, which is expected to increase at a moderate Compound Annual Growth Rate (CAGR) of XX% to XX in 2020. The treatment population for CRC in these markets amounted to an estimated XX in 2013 and is expected to grow at a CAGR of XX% to reach XX in 2020.
2.1 Colorectal Cancer
CRC is the third-most commonly diagnosed cancer and the fourth leading cause of mortality (Haggar and Boushey, 2009). In most developed nations, CRC mortality decreased between 1990 and 2008, attributed to improved early diagnosis and the enactment of national screening programs, aimed at higher-risk parts of the population (generally those over XX years old). In developing nations, as diets become increasingly westernized, incidence is increasing, and national screening programs are still largely nascent.
2.2 Symptoms
CRC sometimes arises without any symptoms or can take XX to XX years to develop, and many symptoms are not apparent until the latter stages of the tumor process. For this reason, regular screening is vital for the detection of tumors in the early stages before advanced progression, when it is more curable, in order to improve patient survival and reduce the cost of CRC treatment.
In spite of this, many cases of CRC are only diagnosed when the patient undergoes emergency admission into hospital, due to complicating symptoms of the disease.
Typical symptoms of CRC, as assessed by the primary care physician, are blood in stool, constipation and diarrhea lasting more than several days, and abdominal discomfort. When physical symptoms are assessed, the patient is then typically referred to secondary care, where a colonoscopy can be administered.
2.3 Epidemiology
The incidence of CRC is far higher than for the other cancers of the Gastrointestinal (GI) tract. An estimated XX of XX cancer incident cases in 2008 were CRC, equivalent to XX% of all cancers (WHO, 2012). Esophageal, gastric, liver and pancreatic cancers accounted for far smaller percentages of the total incident cancer population; there are more patients with CRC than with all of these types of cancer combined.
The five-year prevalence population for CRC in major developed markets amounted to an estimated XX in 2013, which is expected to increase at a moderate CAGR of XX% to XX in 2020. This five-year prevalence is based on annual incidence over five years and takes into account five-year survival rate. This produces a figure that reflects the number of surviving patients diagnosed with CRC over the previous five years, who are more likely to undergo pharmacological treatment for the disease than those diagnosed XX or more years earlier.
The treatment population for CRC in the eight markets covered in this report amounted to an estimated XX in 2013 and is expected to register modest growth to reach XX in 2020 at a CAGR of XX%. Despite the high frequency of the disease, its incidence has been steadily decreasing in the US since the 1980s. Elsewhere, the incidence of CRC has been increasing steadily (Jemal et al., 2011).
CRC incidence is higher in the US and Europe than in Japan due to differences in dietary composition, although incidence in Japan is rapidly increasing due to the westernization of the Japanese diet, which has been ongoing since the 1970s (Kuriki and Tajima, 2006; Jemal et al., 2010). Most cases are diagnosed before distant metastasis has occurred, due to the frequent presentation of early-stage symptoms.
CRC is the third-most commonly diagnosed cancer and the fourth leading cause of mortality.
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 22
3 Marketed Products
3.1 Key Marketed Products
3.1.1 Immunotherapies
3.1.1.1 5-Fluorouracil
5-FU is a pyrimidine analog and acts as an antimetabolite and antineoplastic agent. It is formulated as a solution for injection for the Intravenous (IV) route of administration. 5-FU may be used alone or in combination with other medications for its palliative action in the management of common malignancies such as colon cancer and breast cancer. 5-FU interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. 5-FU can also be incorporated into RNA in place of Uridine Triphosphate (UTP), producing a fraudulent RNA. The drug is available in XXmg, XXmg, XXmg, XXmg and XXmg strength.
3.1.1.2 Xeloda (Capecitabine) – F. Hoffmann-La Roche
Xeloda (capecitabine) is a fluoropyrimidine carbamate with anti-neoplastic activity. The drug is formulated in the form of tablet for oral administration. It is enzymatically converted to 5-FU in the tumor, where it inhibits DNA synthesis and slows the growth of tumor tissue. Xeloda is used as a single agent for the adjuvant treatment of Dukes’ C colon cancer after surgery and as a first-line treatment of metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Xeloda is used for the treatment of metastatic breast cancer in combination with docetaxel, after failure of prior anthracycline-containing chemotherapy. The drug is also used as a monotherapy in the treatment of metastatic breast cancer that is not improved after the treatment with other medicines such as paclitaxel and anthracycline-containing medicine such as doxorubicin. Xeloda is also indicated for the first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 26
3.1.2 Targeted Therapies
3.1.2.1 Avastin (bevacizumab) – F. Hoffmann-La Roche
Avastin is a VEGF-A humanized inhibitor mAb, which is approved for the treatment of metastatic CRC across all eight major markets and is marketed by Roche. The drug is also marketed for the treatment of breast cancer, although its efficacy is far weaker in that indication. Avastin is also indicated for the treatment of kidney and Non-Small-Cell Lung Cancer (NSCLC).
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 34
4 Pipeline Analysis
4.1 Overall Pipeline
The CRC pipeline is highly robust, with potential drug candidates across various phases of clinical development. With nearly XX active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of CRC in advanced stages, either as first-line or second-line therapies. The current investigational pipeline candidates include new combination therapies, targeted therapies and promising immunotherapies, as well as chemotherapy drug candidates. As well as these active progressing pipeline molecules, the pipeline also includes nearly XX molecules that are either inactive or discontinued.
As displayed in the following figure, from XX active progressing pipeline molecules, XX (XX%) are in the Phase II stage of development, XX (XX%) are in the Preclinical stage of development, XX (XX%) are in Phase I, and XX (XX%) are in Phase III. As well as these, a substantial number of active drug candidates are in the discovery stage. As shown in panel B, most of the pipeline drugs are novel, and a few are either generic or products that have already been marketed for other indications.
Figure 4: Colorectal Cancer Therapeutics, Global, Pipeline by Stage of Development and Program Type, 2014
A) Colorectal cancer pipeline by stage of development
B) Colorectal cancer pipeline by program type
Phase I Phase II Phase III
Generic Novel Repositioned
Discovery
Preclinical
Phase I
Phase II
Phase III
IND/CTA-filed
Source: GBI Research, Proprietary Pipeline Products Database
CTA: Clinical Trial Application; IND: Investigational New Drug
With nearly XX active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of CRC in advanced stages, either as first-line or second-line therapies.
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 38
4.4 Clinical Trials
The risk of developing a new chemical entity for the pharmaceutical market is well-documented, and the failure rate of pipeline oncology products appears to be rising in Phase II and III (Lacombe and Liu, 2013). This, in turn, has driven up the average cost of bringing a pharmaceutical product onto the market (Dickson, 2009). With companies therefore seeking to maximize the profitability of their pipeline portfolios, efficient risk management and the selection of only the most promising compounds has become an essential task for pharmaceutical companies.
Additionally, the cost of running clinical trials is high, with the result that clinical pipeline product failures are highly expensive. As the cost of clinical trials is partly driven by the number of patients enrolled, median and mean clinical trial enrollment is a key measure of the relative clinical trial costs for different molecule types.
4.5 Failure Rate
Analysis of CRC clinical trials since 2006 reveals a high failure rate of XX% across all stages of clinical development. Attrition rates of molecules in individual stages of development were XX%, XX% and XX% for Phase I, Phase II and Phase III trials, respectively. The overall failure rates for drugs across the entire industry at each individual phase are estimated at XX% for Phase I, XX% for Phase II and XX% for Phase III (Adams et al., 2010).
Analysis of CRC clinical trials since 2006 reveals a high failure rate of XX% across all stages of clinical development
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 39
Figure 7: Colorectal Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2014
Phase I
Phase II
Phase III
mAbs Small molecule Overall
Phase I
Phase II
Phase III
Specific receptor agonist/antagonist Specific enzyme inhibitors Overall
Overall Small molecule mAbs
Failu
re ra
te (%
)
Source: GBI Research, Proprietary Clinical Trials Database
mAbs: Monoclonal antibody
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 50
5 Market Forecast to 2020
5.1 Global Market
5.1.1 Treatment Use Patterns
The five-year prevalence population of CRC in the eight major markets of the US, the UK, France, Germany, Spain, Italy, Japan and Canada amounted to XX in 2013, which is expected to increase at a moderate CAGR of XX% to XX in 2020. Five-year prevalence is based on annual incidence over five years and takes into account the five-year survival rate. This produces a figure that reflects the number of surviving patients who have been diagnosed with CRC within the last five years and are therefore more likely to undergo pharmacological treatment for the disease than those diagnosed XX or more years earlier. The treatment population for CRC in the eight major markets amounted to XX in 2013 and is expected to register modest growth at a CAGR of XX% to XX in 2020.
5.1.2 Market Size
The value of the CRC therapeutics market in the eight major markets – the US, the UK, France, Germany, Spain, Italy, Japan and Canada – amounted to $XX billion in 2013, and is expected to increase moderately at a CAGR of XX% to $XX billion in 2020, driven by the uptake of a host of new pipeline agents. Of the countries covered in this study, the US represented the largest component of the CRC market in 2013, with a value of $XX billion, or a XX% market share, followed by Japan with $XX billion or XX%, and Germany with $XXm or XX%. Spain had the lowest market share and value of the leading eight at XX% and $XXm.
The five-year prevalence population of CRC in the eight major markets of the US, the UK, France, Germany, Spain, Italy, Japan and Canada amounted to XX in 2013, which is expected to increase at a moderate CAGR of XX% to XX in 2020.
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 51
Figure 10: Colorectal Cancer Therapeutics, Global, Treatment Use Patterns (‘000) and Market Size ($bn), 2013–2020
2013 2014 2015 2016 2017 2018 2019 2020
Pat
ient
s ('0
00)
A) Treatment use patterns
Five-year prevalence population ('000) Treatment population ('000)
2013 2014 2015 2016 2017 2018 2019 2020
Mar
ket s
ize
($bn
)
B) Revenue
Low variance Medium variance High variance Projected
Source: GBI Research, Proprietary Pipeline Products Database; GBI Research, Proprietary Marketed Products Database
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 64
6 Deals and Strategic Consolidations
6.1 Licensing Agreements
A total of XX licensing deals for drugs indicated for CRC were identified from 2006 to 2014, of which 11 had a disclosed deal value, comprising an aggregate deal value of $XX billion. The vast majority of these deals were out-licensed by companies headquartered in the US with the deals being mostly concentrated in South Korea, Japan and Australia in the APAC region.
Almost all deals for which the molecule type of the drug is known concern small molecules, reflecting dominance in the developmental pipeline. The mechanism of action for drugs involved in licensing deals is mostly unknown, but with a slightly higher number of deals concerning cytotoxic agents, growth factor inhibitors and protein kinase inhibitors.
A total of XX licensing deals for drugs indicated for CRC were identified from 2006 to 2014, of which XX had a disclosed deal value, comprising an aggregate deal value of $XX billion.
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 66
Figure 21: Colorectal Cancer Therapeutics, Global, Licensing Deals by Phase, Value, Mechanism of Action, 2006–2014
Pre
clin
ical
Pha
se I
Pha
se II
Pha
se II
I
Mar
kete
d
Und
iscl
osed
Num
ber o
f dea
lsTo
tal d
iscl
osed
dea
l val
ue ($
m)
B) Licensing deals by phase and value
Deal value Upfront payment2006
2007
2008
2009
2010
2011
2012
2013
Agg
rega
te d
eal v
alue
s ($
m)
Num
ber o
f dea
ls
A) Licensing deals by year and deal value
Number of deals with undisclosed valuesNumber of deals with disclosed valuesTotal disclosed value
Und
iscl
osed
Com
bina
tion
Cyt
otox
ic A
gent
s
GF/
GFR
in
hibi
tor/a
ntag
onis
t
Pro
tein
Kin
ase
Inhi
bito
r Agg
rega
ted
deal
val
ue ($
m)
Num
ber o
f dea
ls
C) Licensing deals by mechanism of action and deal value
Number of deals Sum of Upfront paymentSum of Deal Value
Source: GBI Research, Proprietary Deals Database
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 71
7 Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
Table 3 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2014
Product name Company Molecule type Mechanism of action Stage of development
Source: GBI Research, Proprietary Pipeline Products Database
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 72
7.1.2 Preclinical
Table 4 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2014
Product name Company Molecule type Mechanism of action Stage of development
Source: GBI Research, Proprietary Pipeline Products Database
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 73
7.1.3 IND/CTA-Filed
Table 5 Colorectal Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed), 2014
Product name Company Molecule type Mechanism of action Stage of development
Source: GBI Research, Proprietary Pipeline Products Database
7.1.4 Phase I
Table 6 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2014
Product name Company Molecule type Mechanism of action Stage of development
Source: GBI Research, Proprietary Pipeline Products Database
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 74
7.1.5 Phase II
Table 7 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2014
Product name Company Molecule type Mechanism of action Stage of development
Source: GBI Research, Proprietary Pipeline Products Database
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 75
7.1.6 Phase III
Table 8 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2014
Product name Company Molecule type Mechanism of action Stage of development
Source: GBI Research, Proprietary Pipeline Products Database
7.2 Market Forecasts to 2020
7.2.1 Global
Table 9: Colorectal Cancer Therapeutics, Global, Forecast Data, 2013–2020
Year 2013 2014 2015 2016 2017 2018 2019 2020 CAGR (%)
Source: GBI Research, Proprietary Pipeline Products Database; GBI Research, Proprietary Marketed Products Database
7.2.2 US
Table 10: Colorectal Cancer Therapeutics, US, Forecast Data, 2013–2020
Year 2013 2014 2015 2016 2017 2018 2019 2020 CAGR (%)
Source: GBI Research, Proprietary Pipeline Products Database; GBI Research, Proprietary Marketed Products Database
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 76
7.2.3 Canada
Table 11: Colorectal Cancer Therapeutics, Canada, Forecast Data, 2013–2020
Year 2013 2014 2015 2016 2017 2018 2019 2020 CAGR (%)
Source: GBI Research, Proprietary Pipeline Products Database; GBI Research, Proprietary Marketed Products Database
7.2.4 UK
Table 12: Colorectal Cancer Therapeutics, UK, Forecast Data, 2013–2020
Year 2013 2014 2015 2016 2017 2018 2019 2020 CAGR (%)
Source: GBI Research, Proprietary Pipeline Products Database; GBI Research, Proprietary Marketed Products Database
7.2.5 France
Table 13: Colorectal Cancer Therapeutics, France, Forecast Data, 2013–2020
Year 2013 2014 2015 2016 2017 2018 2019 2020 CAGR (%)
Source: GBI Research, Proprietary Pipeline Products Database; GBI Research, Proprietary Marketed Products Database
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 77
7.2.6 Germany
Table 14: Colorectal Cancer Therapeutics, Germany, Forecast Data, 2013–2020
Year 2013 2014 2015 2016 2017 2018 2019 2020 CAGR (%)
Source: GBI Research, Proprietary Pipeline Products Database; GBI Research, Proprietary Marketed Products Database
7.2.7 Italy
Table 15: Colorectal Cancer Therapeutics, Italy, Forecast Data, 2013–2020
Year 2013 2014 2015 2016 2017 2018 2019 2020 CAGR (%)
Source: GBI Research, Proprietary Pipeline Products Database; GBI Research, Proprietary Marketed Products Database
7.2.8 Spain
Table 16: Colorectal Cancer Therapeutics, Spain, Forecast Data, 2013–2020
Year 2013 2014 2015 2016 2017 2018 2019 2020 CAGR (%)
Source: GBI Research, Proprietary Pipeline Products Database; GBI Research, Proprietary Marketed Products Database
7.2.9 Japan
Table 17: Colorectal Cancer Therapeutics, Japan, Forecast Data, 2013–2020
Year 2013 2014 2015 2016 2017 2018 2019 2020 CAGR (%)
Source: GBI Research, Proprietary Pipeline Products Database; GBI Research, Proprietary Marketed Products Database
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 78
7.3 Market Definitions
Market Coverage
The market includes the eight major markets: the US, the UK, France, Germany, Spain, Italy, Japan and Canada.
The prevalence population is the estimated number of people at any given point of time that are affected by CRC.
The prescription population refers to the number of people taking pharmacological treatment for CRC.
7.4 Abbreviations
5-FU: 5-Fluorouracil
5T4: Trophoblast glycoprotein
ACoT: Annual Cost of Therapy
AE: Adverse Event
Ang: Angiopoietin
APC: Adenomatous Polyposis Coli
ASCO: American Society of Clinical Oncology
ATP: Adenosine Triphosphate
BSC Best Supportive Care
CAGR: Compound Annual Growth Rate
CDF: Cancer Drug Fund
CDK: Cyclin-Dependent Kinase
CEA: Carcinoembyonic Antigen
cGMP-PDE: cyclic Guanosine Monophosphate-Phosphodiesterase
CI: Confidence Interval
CMS: Centers for Medicare & Medicaid Services
CNS: Central Nervous System
CRC: Colorectal Cancer
CTA: Clinical Trial Application
DFMO: Difluoromethylated Ornithine
DFS: Disease Free Survival
DPD: Dihydropyrimidine Dehydrogenase
DTH: Delayed Type Hypersensitivity
dThd: degrading deoxythymidine
ECOG: Eastern Cooperative Oncology Group
EGFR: Epidermal Growth Factor Receptor
EMA: European Medicines Agency
FA: Folinic Acid
FAP: Familial Adenomatous Polyposis
FDA: Food and Drug Administration
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 79
FdUMP: 5-fluoro-2'-deoxyuridine monophosphate
FFPE: Formalin-Fixed Paraffin Embedded
FGF: Fibroblast Growth Factor
FGFR: Fibroblast Growth Factor Receptor
FLT3: FMS-Like Tyrosine Kinase 3
FOB: Fecal Occult Blood
FUTP: 5-Fluorouridine Triphosphate
GBM: Glioblastoma Multiforme
GEJ: Gastroesophageal Junction
GI: Gastrointestinal
GIST: Gastrointestinal Stromal Tumors
HDAC: Histone Deacetylases
HER: Human Epidermal Growth Factor Receptor
HGFR: Hepatocyte Growth Factor Receptor
HIPEC: Hyperthermic Intraperitoneal Chemotherapy
HNPCC: Non-Polyposis Colorectal Cancer
HR: Hazard Ratio
IDO: Indoleamine Pyrrole 2,3-Dioxygenase
IGF: Insulin-like Growth Factor
IgG1: Immunoglobulin G1
IL: Interleukin
IND: Investigational New Drug
IPF: Idiopathic Pulmonary Fibrosis
IV: Intravenous
JAK: Janus Kinase 2
kg:
K-Ras: Kirsten rat sarcoma viral oncogene homolog
LV: Leucovorin
m2: square meter
mAb: monoclonal antibody
MAPK: Mitogen-Activated Protein Kinase
MCC: Mutated-in-Colon-Cancer
mCRC: metastatic CRC
mg: milligram
MHLW: Ministry of Health, Labor and Welfare
MLH1: MutL Homolog
MSH: MutS Homolog
mTOR: mammalian Target of Rapamycin
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 80
MUC: Mucin
NCI: National Cancer Institute
NF-kB; Nuclear Factor kappa B
NHI: National Health Insurance
NHS: National Health Service
NSCLC: Non-Small-Cell Lung Cancer
ODC: Ornithine Decarboxylase
OPRT: Orotate Phosphoribosyl-Transferase
OS: Overall Survival
p53: tumor protein 53
PACES: Preventing Adenomas of the Colon with Eflornithine and Sulindac
PARP-1: Poly (ADP-Ribose) Polymerase 1
PDE: Phosphodiesterase
PDGF: Platelet Derived Growth Factor
PDGFR: PDGF Receptor
PEG: Polyethylene Glycol
PFS: Progression-Free Survival
PI3K: Phosphatidylinositol-3-Kinase
PIGF: Placental Growth Factor
PKB: Protein Kinase B
PMS: Postmeiotic Segregation Increased
PS: Performance Status
RCC: Renal Cell Carcinoma
RECIST: Response Evaluation Criteria in Solid Tumors
RhD: Rhesus D
RNA: Ribonucleic Acid
RR: Response Rate
SWOG: Southwest Oncology Group
TKI: Tyrosine Kinase Inhibitor
TLR: Toll-Like Receptor
TNIK: TRAF2 and NCK-Interacting Protein Kinase
TNM: Tumor, Nodes and Metastasis
TPI: Thymidine Phosphorylase Inhibitor
TS: Thymidylate Synthase
TTP: Thrombotic Thrombocytopenic Purpura
UTP: Uridine Triphosphate
V2R: Vasopressin V2 Receptor
V1aR: Vasopressin V1a Receptor
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 81
V1bR: Vasopressin V1b Receptor
VEGF: Vascular Endothelial Growth Factor
VEGFR: VEGF Receptor
7.5 References
Adams C and Brantner V (2010). Spending on New Drug Development. Health Economics; 19: 130–141.
Abdullah L and Chow E (2013). Mechanisms of chemoresistance in cancer stem cells. Clinical and Translational Medicine; 2(1): 3
Amado RG, et al. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology; 26(10):1626–1634
Amgen (2013). Annual Report and 10-K Filings. Amgen. Available from: http://quote.morningstar.com/stock-filing/Annual-Report/2013/12/31/t.aspx?t=XNAS:AMGN&ft=10-K&d=3ce2d871c79191e361b6b2aa40d97ee2 [Accessed on: November 04, 2014]
Balmaña J et al. (2010). Familial colorectal cancer risk: ESMO Clinical Practice Guidelines. Annals of Oncology; 21(suppl 5): v78-v81
Bibeau F et al. (2006). Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray. Virchows Archiv; 449(3): 281–287
Bruni L et al. (2014). ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report 2014-02-20. HPV Information Centre. Available from: http://www.hpvcentre.net/dataquery.php [Accessed October 27, 2014]
Calle EE and Thun MJ (2004). Obesity and cancer. Oncology; 23(38): 6365–6378
Cappell MS (2005). The pathophysiology, clinical presentation, and diagnosis of colon cancer and adenomatous polyps. The Medical Clinics of America: 89(1): 1–42, vii
Center MM et al. (2009a). International trends in colorectal cancer incidence rates. Cancer Epidemiology, Biomarkers and Prevention; 18(6): 1688–1694
Center MM et al. (2009b). Worldwide variations in colorectal cancer. CA: A Cancer Journal for Clinicians; 59(6): 366–378
Chiron M et al. (2014). Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Molecular Cancer Therapeutics; 13(6):1636–44
Colagiuri B et al. (2012). Does Assessing Patients’ Expectancies About Chemotherapy Side Effects Influence Their Occurrence? Journal of Pain and Symptom Management; Epub
Corley DA et al. (2014). Adenoma detection rate and risk of colorectal cancer and death. New England Journal of Medicine; 370(14): 1298–1306
Cutsem E, et al. (2007). Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology; 25 (13): 1,658–1,664.
Dickson M (2009). The Cost of New Drug Development. Discovery Medicine; 4 (22): 172–179.
Dolgin E (2009), FDA narrows drug label usage. Nature Publishing Group. Available from: http://www.nature.com/news/2009/090824/full/4601069a.html [Accessed on: September 10, 2014]
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 86
7.6 References for Heat Map
Table 18: Colorectal Cancer Market, References for Heat Map
Number Reference
1 Giantonio B et al. (2007). Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology; 25 (12): 1,539–1,544.
2 Grothey A et al. (2012). Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE). Journal of Clinical Oncology; 26 (33): 5,326–5,344.
3 Hurwitz H et al. (2004). Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. New England Journal of Medicine; 350 (23): 2,335–2,342.
4 Kabbinavar et al. (2005). Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer.
5 Kabbinavar F et al. (2009). Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials. Journal of Clinical Oncology; 23 (16): 3,706–3,712.
6 Miller K et al. (2005). Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer. Journal of Clinical Oncology; 23 (4): 792–799.
7 Saltz L et al. (2008). Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology; 26 (12): 2,013–2,019.
8 Grothey A et al. (2012). CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22.
9 Kim T W (2014). "CONCUR: A randomized, placebo-controlled phase 3 study of regorafenib (REG) monotherapy in Asian patients with previously treated metastatic colorectal cancer (mCRC)", European Society for Medical Oncology (ESMO) 2014 Congress, Category: Gastrointestinal tumors, colorectal, Session: Proffered Paper session, Poster No.: 500O, 27 Sep 2014
10 Van Cutsem et al. (2013). Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014 Jan;50(2):320-31. doi: 10.1016/j.ejca.2013.09.013. Epub 2013 Oct 16.
11 Amado R et al. (2008). Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology; 26 (10): 1,626–1,634.
12 Cutsem E et al. (2007). Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology; 25 (13): 1,658–1,664.
13 Douillard J et al. (2010). Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. Journal of Clinical Oncology; 28 (31): 4,697–4,705.
14 Hecht J et al. (2009). A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. Journal of Clinical Oncology; 27 (5): 672–680.
15 Peeters M et al. (2010). Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology; 28 (31): 4,706–4,713.
16 Tol J et al. (2008). A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Annals of Oncology; 19: 734–738.
17 Maughan T et al. (2011). Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomized phase 3 MRC COIN trial. Lancet; 377: 2,103–2,114.
18 Sobrero A et al. (2008). EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology; 26 (14): 2,311–2,319.
Source: GBI Research
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 87
7.7 Research Methodology
GBI Research’s dedicated research and analysis teams consist of experienced professionals with advanced statistical expertise and marketing, market research and consulting backgrounds in the medical devices industry.
GBI Research adheres to the codes of practice of the Market Research Society (www.mrs.org.uk) and Strategic and Competitive Intelligence Professionals (www.scip.org).
All GBI Research databases are continuously updated and revised. The following research methodology is followed for all databases and reports.
7.7.1 Coverage
The objective of updating GBI Research coverage is to ensure that it represents the most up-to-date vision of the industry possible.
Changes to the industry taxonomy are built on the basis of extensive research of company, association and competitor sources.
Company coverage is based on three key factors: market capitalization, revenues and media attention/innovation/market potential.
An extensive search of 56 member exchanges is conducted, and companies are prioritized on the basis of their market capitalization.
The estimated revenues of all major companies, including private and governmental, are gathered and used to prioritize coverage.
Companies that are making the news or that are of particular interest due to their innovative approach are prioritized.
GBI Research aims to cover all major news events and deals in the pharmaceutical industry, updated on a daily basis.
The coverage is further streamlined and strengthened with additional inputs from GBI Research’s expert panel.
7.7.2 Secondary Research
The research process begins with extensive secondary research using internal and external sources to gather qualitative and quantitative information relating to each market.
The secondary research sources that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Industry trade journals, scientific journals and other technical literature
Internal and external proprietary databases
Relevant patent and regulatory databases
National government documents, statistical databases and market reports
Procedure registries
News articles, press releases and web-casts specific to the companies operating in the market
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 88
7.7.3 Primary Research
GBI Research conducts hundreds of primary interviews a year with industry participants and commentators in order to validate its data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape and future outlook
Helps to validate and strengthen secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves email correspondence, telephone interviews and face-to-face interviews for each market, category, segment and sub-segment across a range of geographies.
The participants who typically take part in the process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
Distributors, paramedics and representatives from hospital stores, laboratories and pharmacies
Outside experts: investment bankers, valuation experts, research analysts specializing in specific pharmaceutical markets
Key opinion leaders: physicians and surgeons that specialize in the therapeutic areas
7.7.4 Therapeutic Landscape
Revenues for each indication, geographically, are arrived at by utilizing the GBI Research market-forecasting model. The global revenue for each indication is the sum value of revenues of all eight regions.
The annual cost of therapy for each indication is arrived at by considering the cost and dosage of the drugs and the duration of the therapy.
The generic share of the market for each indication is obtained by calculating the prescription share for generic drugs and the respective cost of treatment.
The treatment-use pattern, which includes quantitative data on the diseased population, treatment-seeking population, diagnosed population and treated population for an indication, is arrived at by referring to various sources as mentioned below.
GBI Research uses the epidemiology-based treatment flow model to forecast market size for therapeutic indications.
The forecasting model used by GBI Research makes use of epidemiology data gathered from research publications and primary interviews with physicians to represent the treatment flow patterns for individual diseases and therapies. The market for any disease segment is directly proportional to the volume of units sold and the price per unit.
Sales = Volume of Units sold x Price per Unit
The volume of units sold is calculated on the average dosage regimen for that disease, duration of treatment, and number of patients that are prescribed drug treatment (prescription population).
Prescription population is calculated as the percentage of the population diagnosed with a disease (diagnosis population). Diagnosis population is the population diagnosed with a disease expressed as a percentage of the population that is seeking treatment (treatment-seeking population). Prevalence of a disease (diseased population) is the percentage of the total population that suffers from a disease/condition.
Data on the treatment-seeking rate, diagnosis rate and prescription rate, if unavailable from research publications, are gathered from interviews with physicians and are used to estimate the patient volumes for the disease under consideration. Therapy uptake and compliance data are fitted into the forecasting model to account for patient switching and compliance behavior.
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 89
To account for differences in patient affordability of drugs across various geographies, macro-economic data such as inflation and GDP; and healthcare indicators such as healthcare spending, insurance coverage and average income per individual are used.
Annual cost of therapy is calculated using product purchase frequency and the average price of the therapy. Product purchase frequency is calculated from the dosage data available for the therapies, and drug prices are gathered from public sources.
The epidemiology-based forecasting model uses a bottom-up methodology and makes use of estimations in the absence of data from research publications. Such estimations may result in a final market value which is different from the actual value. To correct this ‘gap’ the forecasting model uses ‘triangulation’ with the help of base year sales data (from company annual reports, internal and external databases) and sales estimations.
Analogous Forecasting Methodology
Analogous forecasting methodology is used to account for the introduction of new products, patent expiries of branded products and the subsequent introduction of generics. Historical data for new product launches and generics penetration are used to arrive at robust forecasts. Increase or decrease in prevalence rate, treatment-seeking rate, diagnosis rate and prescription rate are fitted into the forecasting model to estimate market growth rate.
The proprietary model enables GBI Research to account for the impact of individual drivers and restraints on the growth of the market. The year and the extent of impact are quantified in the forecasting model to provide close-to-accurate data sets.
Diseased Population
The diseased population for any indication is the prevalence. The prevalence rates are usually obtained from various journals, online publications, sources such as the World Health Organization or associations and foundation websites for that particular disease.
Prescription Population
For any disease, multiple treatment options exist. For example, in cancer treatment various treatment options such as surgery, radiation therapy and drug therapy are available. The prescription population is defined as the number of patients that are prescribed drug therapy. This is calculated as a percentage of the diagnosis population. The prescription population is primarily driven by the age at which the disease is diagnosed, the disease stage, patient health and the cost of drug treatment.
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 90
7.7.4.1 Market Size by Geography
The treatment-use pattern and annual cost of therapy in each country has been factored in when deriving the individual country market size.
Forecasting Model for Therapeutic Areas
Figure 23: GBI Research Market Forecasting Model
D is ease P opu lati onGener al Po pulatio n 743,535,048
Q uali fying c ondi tion 1 (Age /S ex/O c c upation e tc )Q uali fying c ondi tion 2 (Age /S ex/O c c upation e tc )
Preva l ence t issu e va lve disease 0.2% 1,784,484 Q uali fying c ondi tion (c om plic ation, s eve rity)DIS EA SE D P OPU LA T IO N 1,784,484
T r eatm en t Flow P a ttern sT rea tm ent S eek i ng R at e (Sy m ptom s / Dis Awareness) 89% 1,588,191 Diagn os is Rat e (C lin ical and D iagn os tic Tes t s) 75% 1,191,143
Prescr iption R ate ( Ph ys ician P ercep t io n, Tr eatm ent E ffectiv e n ess )Tis s ue V a lve 70% 833,800 O ther T reatm ents for Valve (Su r g/M ed /N one) -
F ulfi llm en tA vailab ilit y NAW illingness to Us e (Pa tient Perc eptions) NAReady to U se (S u rge ry elig ib ility , R eus e etc ) NA
Affo rd abil it y a t PriceHE as % of G DP s pendA verage Inc om e (per individua l)P at ien t O u t-o f -poc ket Budge t (A nnual)
Budget al loc a tion to one-t im e s urge ryBudget al loc a tion to o the r h ealth needs
A verage Pay or CoverageP at ien t L iab ilityTarge t Pr ic e ( @ 20% pat liab )A SP for C os t o f T herapy
T O TA L P AT IEN T V OLU M E SPro du ct P urch ase Fr equ en c y 1
T OT AL U NIT VO LU MES
Pr icin g pe r Un it 18 ,000$ In f lat ionP rice D ec reas e due to c om pet it ion
M ar ket Va lu e
G BI R esear ch M ar ket Siz in g M o del
Source: GBI Research
The preceeding figure represents a typical forecasting model followed by GBI Research. As discussed previously, the model is built on treatment flow patterns. The model starts with the general population, then the diseased population as a percentage of the general population, and then follows the treatment-seeking population as a percentage of the diseased population, and diagnosed population as a percentage of the treatment seeking population. Finally, the total volume of units sold is calculated by multiplying the treated population by the average dosage per year per patient.
© GBI Research. This is a licensed product and is not to be photocopied
GBIHC352MR / Published JAN 2015 Page 91
7.7.5 Geographical Landscape
GBI Research analyzes eight major geographies: the US, the top five countries in Europe (the UK, Germany, France, Spain and Italy),Japan and Canada. The total market size for each country is provided, which is the sum value of the market sizes of all the indications for that particular country. The maximum and minimum estimated market sizes are then provided by adjusting all variables expected to impact upon the market during the forecast period in order to provide the best-case and worst-case scenarios.
Articles from research journals and agency publications such as Rheumatology, Annals of the Rheumatic Diseases, National Institute of Health and ClinicalTrials.gov are the source of data for the estimation of market size and making forecasts.
7.7.6 Pipeline Analysis
This section provides a list of molecules at various stages in the pipeline for various indications. The list is sourced from an internal database and validated for accuracy of phase and mechanism of action at ClinicalTrials.gov and company websites. The section also includes a list of promising molecules which is narrowed down based on the results of the clinical trials at various stages, and the novelty of mechanism of action. A heat map, sourced from relevant clinical trials, is provided in order to compare these products to one another, in addition to currently marketed products. The latest press releases issued by the companies and news reports are also used to source information for the status of the molecule in the pipeline. This list of pipeline molecules, in conjunction with a list of ongoing and completed clinical trials, is analyzed in this section, and a full breakdown of pipeline molecules and clinical trials by Phase, molecule type and molecular target is provided.
7.8 Expert Panel Validation
GBI Research uses a panel of experts to cross verify its databases and forecasts.
GBI Research expert panel comprises marketing managers, product specialists, international sales managers from pharmaceutical companies, academics from research universities and key opinion leaders from hospitals.
Historical data and forecasts are relayed to GBI Research’s expert panel for feedback and are adjusted in accordance with their feedback.
7.9 Contact Us
If you have any queries about this report or would like further information, please contact:
North America: +1 646 395 5477
Europe: +44 (0) 207 406 6777
Asia-Pacific: +91 40 6616 6878
E-mail: [email protected]
7.10 Disclaimer
All Rights Reserved.
No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GBI Research.
The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that GBI Research delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such, GBI Research can accept no liability whatsoever for actions taken based on any information that may subsequently prove to be incorrect.